🇺🇸 FDA
Patent

US 9005599

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

granted A61KA61K2035/124A61K2039/505

Quick answer

US patent 9005599 (Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents) held by Tissue Regeneration Therapeutics Inc. expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tissue Regeneration Therapeutics Inc.
Grant date
Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K2239/31, A61K35/44